627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin

Golseek 1 A Phase 3 double blind randomized study of golcadomide GOLCA a potential first in class oral CELMoD™ agent R CHOP vs placebo R CHOP in patients with previously untreated high risk large B cell lymphoma

Trial in progress A phase 3 multi regional open label randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed Refractory primary central nervous system lymphoma

Real world study of rituximab methotrexate and zanubrutinib  R MZ  in the treatment of newly diagnosed primary central nervous system lymphoma

Polatuzumab vedotin plus R CHP demonstrates high efficacy with manageable toxicity in treatment Naïve dual expressor DLBCL DEL Real world analysis with focus on elderly high risk patients

Rituximab cyclophosphamide mitoxantrone hydrochloride liposome vincristine and prednisone R CMOP in elderly patients with newly diagnosed diffuse large B cell lymphoma A multicenter prospective study

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy free therapy in relapsed or refractory primary central nervous system lymphoma

Long term clinical outcomes from the smart start trial Rituximab lenalidomide and ibrutinib in patients with newly diagnosed large B cell lymphoma

Efficacy and safety of vipor P in relapsed or refractory large B cell lymphoma

Effectiveness and toxicity of cyclophosphamide etoposide and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non Hodgkin lymphoma

BGB 3111 218 Single arm open label multicenter study of the Bruton tyrosine kinase BTK inhibitor zanubrutinib zanu in patients with CD79B mutated Relapsed Refractory R R diffuse large B cell lymphoma DLBCL

Pola R edch shows high response rates in high risk aggressive B cell lymphomas or PMBCL A phase 2 study

Pola R CHP in newly diagnosed primary mediastinal B cell lymphoma high efficacy and tolerability

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation PolaR EPCH